🚀 Wall Street Radar: Stocks to Watch Next Week
💼 Volume 47: 📈 S&P 500 Hits Record High Amid 'Goldilocks' Jobs Data
Portfolio updates and new positions:
⚡ AI-optimized, human-verified: Our expert team carefully selected Premium market intelligence from Fiscal.ai data. Explore now →
T2118
This week, the T2118 indicator made a significant upward move. While it has not yet reached the 90.00 "danger zone" level, it could potentially get there within the next one to two weeks. Concurrently, the VIX has stabilized below 20, currently at 16.38, which suggests that market conditions are calm for the time being.
However, we remain cautious as our indicators are signaling overextension in both the SPY and QQQ, although not yet in the IWM. Our analysis tends to be early, so it is possible the market could continue to climb slightly higher from current levels. We will seek to capitalize on opportunities as they arise, while maintaining extreme caution due to the increasing likelihood of an imminent pullback.
Our current positions in DGXX and BULL are performing well. With stop-losses moved to break-even, both trades have been effectively de-risked, leaving no cause for immediate concern. The primary challenge now is to identify new opportunities in themes and sectors that are not yet overextended or overly hyped.
For real-time updates on our positioning, trade ideas, and market commentary as conditions evolve, our chat remains the best resource for staying connected with our analysis and decision-making process.
T2108
T2108 closed the week at 69.28, rising strongly from the previous week. What's particularly noteworthy is its behavior relative to other market measures. The indicator is matching the same behaviour of the T2118, giving us a clear picture of a strong trend aligned with both indicators. This alignment across our key indicators provides a clear directional consensus, suggesting the participation is broad and most sectors are participating in this uptrend.
The 4% Bull-Bear Indicator provided some insight into the week's character, giving us a clear picture of where the bulls were dominant this week. This short-term measure reflects the decisive nature of current market dynamics, with bulls establishing a clear presence.
The 25% Bull-Bear Indicator is giving a more defined picture. We are seeing the long term indicator not only telling us that bulls are dominating, but also that the participation overall is increasing more. This growing bullish conviction, which has strengthened considerably, adds another layer of confirmation.
Latest articles:
🌱 Support Our Work: Buy Us a Coffee or Shop Our Services! 🌱
Your small gesture fuels our big dreams. Click below to make a difference today.
[☕ Buy Us a Coffee]
[🛒 Visit Our Shop]
Each stock on the watchlist will now have a risk grade badge next to its name, reflecting our assessment based on factors such as volatility, share float, technicals, fundamentals, ADR, and more. This badge is designed to help readers gauge the stock's risk profile, providing valuable context for making informed decisions about approaching it.
High risk: ⚠️
Medium Risk: 📊
Low Risk: 🛡️
🆓✨ Watchlist Essentials: Top Free Picks
NBIS: Nebius Group NV ⚠️
What they do: AI infrastructure and cloud computing services provider
Why watch? 🤖 After a strong run, NBIS is consolidating just below $51.00 key level. The stock found solid support at the rising 20-day Exponential Moving Average (EMA) and printed an inside day on Friday, suggesting a potential pause before the next move. A brief pullback for another day or two could create an ideal setup for a breakout over the $51.00 level, potentially igniting a march to new highs. The reaction in the broader tech and semiconductor sectors on Monday will be a key tell.
HIMS: Hims & Hers Health, Inc.⚠️
What they do: A multi-specialty telehealth platform providing modern, personalized health and wellness experiences
Why watch? 💊 Following a sharp plunge on recent news, HIMS has impressively recouped a significant portion of its losses. The stock is now forming a small flag pattern directly beneath a cluster of its main moving averages. This is a high-risk setup, as the stacked moving averages present formidable overhead resistance that could lead to a failed breakout. However, if the broader market remains strong, a decisive push could break through this resistance and lead to a significant gap fill.
OKLO: Oklo Inc. ⚠️
What they do: An advanced fission technology and nuclear fuel recycling company developing next-generation power plants.
Why watch? ⚛️ After showing relative weakness last week while the market pushed higher, OKLO appears to be tracing out a classic technical pattern. The stock has completed the "cup" portion and now seems to be finalizing the "handle." A confirmed breakout would occur on a move over the $58.00 level, though aggressive traders might consider an initial position on a break above $55.00.
NVTS: Navitas Semiconductor Corp. ⚠️
What they do: A designer and manufacturer of gallium nitride (GaN) power integrated circuits that enable high-efficiency power conversion.
Why watch? ⚡ Following a powerful 120% surge from its recent gap-up day, NVTS is now taking a well-deserved rest near its 20-day EMA. Notably, the trading volume is dwindling, with six consecutive days of lower volume—a classic indication that sellers are exhausted and the stock is consolidating in strong hands. A break above the $6.50 - $6.75 zone could provide the spark for the next major leg higher.
Put the market on autopilot, experience the Best Platform with TC2000
Explore now →
💎📈 Watchlist Elite: Premium Market Movers
Each selection undergoes rigorous financial analysis, technical evaluation, and strategic assessment, delivering institutional-grade research.
Every week, we showcase one complete premium analysis at no cost, letting you experience firsthand the depth and quality that sets Elite research apart.
CDTX: Cidara Therapeutics ⚠️
What they do: A biotechnology company developing long-acting therapeutics, including CD388, a promising universal flu shot candidate.
Why watch? 🧬 Cidara's value has skyrocketed after presenting stellar Phase 2b trial results for its main asset, CD388. The drug, a long-acting antiviral, demonstrated up to 76% protection against symptomatic seasonal influenza with a compelling safety profile. This isn't a traditional vaccine; it's a prophylactic designed to complement existing flu shots, giving it a unique and potentially vast market position, especially for high-risk patients. A recent, albeit dilutive,$250 million capital raise has significantly de-risked the company's financial position, providing a clear runway to initiate pivotal Phase 3 trials and navigate the path to potential approval within a $13 billion addressable market.
Keep reading with a 7-day free trial
Subscribe to Market Moves by GBC to keep reading this post and get 7 days of free access to the full post archives.